Answers are grounded in this paper and cite their sources.
An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa. Although infrequent, other similar reports highlight the need for ongoing trials evaluating erythropoietin receptor agonists to ensure that overall survival is monitored closely.
No takes yet. Share an insight, caveat, or question.
Wright et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: